PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

July 2, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO.	APPLICATION NO.	
2907.1000-003	10/686,943	
APPLICANT		
Adrian V.S. Hill, *et al.*		
FILING DATE	CONFIRMATION NO.	GROUP
October 16, 2003	4585	1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
LWH	AA	5,110,587	May 5, 1992	Paoletti, *et al.*
	AB	5,185,146	February 9, 1993	Altenburger
	AC	5,225,336	July 6, 1993	Paoletti
	AD	5,453,364	September 26, 1995	Paoletti
	AE	5,766,597	June 16, 1998	Paoletti, *et al.*
	AF	6,663,871 B1	December 16, 2003	McMichael, *et al.*
	AG	US-2003-0138454-A1	July 24, 2003	Hill, *et al.*
	AH			
	AI			
	AJ			
	AK			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
LWH	AL	WO 97/39771	October 30, 1997	The Gov. of the U.S.		
LWH	AM	WO 98/04728	February 5, 1998	Therion Biologics Corporation		
LWH	AN	WO 96/26271	August 29, 1996	Therion Biologics Corporation		
	AO					
	AP					
	AQ					

EXAMINER	DATE CONSIDERED
/Louise Humphrey/	06/20/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2907.1000-003	10/686,943	
	APPLICANT Adrian V.S. Hill, *et al.*		
July 2, 2004	FILING DATE October 16, 2003	CONFIRMATION NO. 4585	GROUP 1648
(Use several sheets if necessary)			

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
LWH	AR	Ada, G., "Do Cytotoxic T Lymphocytes Clear Some HIV/SIV Infections?," *J. Med. Primatol. 25*(3):158-162 (June 1996).
	AS	Aidoo, M., *et al.*, "Identification of Conserved Antigenic Components For a Cytotoxic T Lymphocyte-Inducing Vaccine Against Malaria," *Lancet 345*(8956):1003-1007 (Apr. 22, 1995).
	AT	Aidoo, M., *et al.*, "Recombinant Vaccinia Viruses for the Characterization of *Plasmodium falciparum*-specific Cytotoxic T Lymphocytes: Recognition of Processed Antigen Despite Limited Re-Stimulation Efficacy," *Intl. Immunol. 9*(5):731-737 (Jan. 1997).
	AU	Allsopp, C.E.M., *et al.*, "Comparison of Numerous Delivery Systems for the Induction of Cytotoxic T Lymphocytes By Immunization," *Eur. J. Immunol. 26*:1951-1959 (1996).
	AV	Blanchard, T., *et al.*, "Future Vaccines for HIV," *Lancet 348*(9043):1741 (Dec. 1996).
	AW	Blanchard, T.J., *et al.*, "Modified Vaccinia Virus Ankara Undergoes Limited Replication in Human Cells and Lacks Several Immunomodulatory Proteins: Implications for Use as a Human Vaccine," *J. Gen. Virol. 79*:1159-1167 (1998).
	AX	Carroll, M.W., *et al.*, "Highly Attenuated Modified Vaccinia Virus Ankara (MVA) as an Effective Recombinant Vector: A Murine Tumor Model," *Vaccine 15(4):387-394 (1997).*
	AY	Chamberlain, R.S., *et al.*, "Use of Multiple Vaccination Vectors for the Generation of CTL Against a Model Tumor Antigen," *Proceedings of the Annual Meeting of the American Association for Cancer Research* (Washington, April 20-24, 1996, 37, Abstract No. 3263).
	AZ	Doolan, D.L., "The Complexity of Protective Immunity Against Live-Stage Malaria," *J. Immunol., 165(3):*1453-1462 (2000).
	AR2	Doolan, D.L., *et al.*, "Circumventing Genetic Restriction of Protection against Malaria with Multigene DNA Immunization: $CD8^+$ T Cell-, Interferon γ-, and Nitric Oxide-Dependent Immunity," *J. Exp. Med. 183*(4):1739-1746 (April 1996).
↓	AS2	Fuller, D.H., *et al.*, "Gene Gun-Based Nucleic Acid Immunization Alone or in Combination with Recombinant Vaccinia Vectors Suppresses Virus Burden in Rhesus Macaques Challenged with a Heterologous SIV," *Immunol. Cell Biol. 75*(4):389-396 (Aug. 1997).

EXAMINER	/Louise Humphrey/	DATE CONSIDERED	06/20/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2907.1000-003	10/686,943	
July 2, 2004	APPLICANT: Adrian V.S. Hill, *et al.*		
(Use several sheets if necessary)	FILING DATE: October 16, 2003	CONFIRMATION NO.: 4585	GROUP: 1648

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
LWH	AT2	Fuller, D.H., *et al.*, "Enhancement of Immunodeficiency Virus-Specific Immune Responses in DNA-Immunized Rhesus Macaques," *Vaccine, 15*(8):924-926 (June 1997).
	AU2	Gallimore, A., *et al.*, "Early Suppression of SIV Replication By $CD8^+$ *nef*-specific Cytotoxic T Cells In Vaccinated Macaques," *Nature Med. 1*(11):1167-1173 (Nov. 1995).
	AV2	Gilbert, S.C., *et al.*, "A Protein Particle Vaccine Containing Multiple Malaria Epitopes," *Nat. Biotechnol., 15(12):*1280-1284 (1997).
	AW2	Greenspan, N.S., *et al.*, "Defining Epitopes: It's Not As Easy As It Seems," *Nature Biotechnology* 7:936-937 (1999).
	AX2	Hanke, T., *et al.*, "Immunogenicities of Intravenous and Intramuscular Administrations of Modified Vaccinia Virus Ankara-Based Multi-CTL Epitope Vaccine for Human Immunodeficiency Virus Type 1 in Mice," *J. Gen. Virol. 79*:83-90 (1998).
	AY2	Hanke, T., *et al.*, "Enhancement of MHC Class I-Restricted Peptide-Specific T Cell Induction by a DNA Prime/MVA Boost Vaccination Regime," *Vaccine 16*(5):439-445 (1998).
	AZ2	Hanke, T., *et al.*, "DNA Multi-CTL Epitope Vaccines for HIV and *Plasmodium falciparum*: Immunogenicity in Mice," *Vaccine 16*(4):426-435 (1998).
	AR3	Hill, AV, "DNA-Based Vaccines for Malaria: a Heterologous Prime-Boost Immunisation Strategy," *Dev. Biol. (Basel), 104:*171-179 (2000).
	AS3	Hill, A.V.S., *et al.*, "Common West African HLA Antigens Are Associated With Protection From Severe Malaria," *Nature 352*(6336):595-600 (Aug. 15, 1991).
	AT3	Hirsch, V.M., *et al.*, " Patterns of Viral Replication Correlate with Outcome in Simian Immunodeficiency Virus (SIV)-Infected Macaques: Effect of Prior Immunization with a Trivalent SIV Vaccine in Modified Vaccinia Virus Ankara," *J. Virol. 70*(6):3741-3752 (June 1996).
	AU3	Hodge, J.W., *et al.*, "Diversified Prime and Boost Protocols Using Recombinant Vaccinia Virus and Recombinant Non-Replicating Avian Pox Virus to Enhance T-Cell Immunity and Antitumor Responses," *Vaccine 15*(6/7):759-768 (April/May 1997).
↓	AV3	Tascon, R. *et al.*, "Vaccination Against Tuberculosis by DNA Injection," *Nat. Med.* 2: 893-898 (1996).

EXAMINER	/Louise Humphrey/	DATE CONSIDERED	06/20/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2907.1000-003	10/686,943	
July 2, 2004	APPLICANT: Adrian V.S. Hill, *et al.*		
(Use several sheets if necessary)	FILING DATE: October 16, 2003	CONFIRMATION NO.: 4585	GROUP: 1648

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
LWH	AW3	Irvine, K.R., *et al.*, "Route of Immunization and the Therapeutic Impact of Recombinant Anticaner Vaccines," *J. Natl. Cancer Inst. 89*(5):390-392 (March 1997).
	AX3	Irvine, K.R., *et al.*, "Enhancing Efficacy of Recombinant Anticancer Vaccines With Prime/Boost Regiments That Use Two Different Vectors," *J. Natl. Cancer Inst. 89*(21):1595-1601 (Nov. 1997).
	AY3	Lalvani, A., *et al.*, "An HLA-Based Approach to the Design of a CTL-Inducing Vaccine Against *Plasmodium falciparum*," *Research in Immunology 145*(6):461-468 (1994).
	AZ3	Lanar, D.E., *et al.*, "Attenuated Vaccinia Virus-Circumsporozoite Protein Recombinants Confer Protection against Rodent Malaria," *Infec. Immun. 64*(5):1666-1671 (May 1996).
	AR4	Layton, F.T., *et al.*, "Induction of Single and Dual Cytotoxic T-Lymphocyte Responses to Viral Proteins in Mice Using Recombinant Hybrid Ty-Virus-Like Particles," *Immunology 87*(2):171-178 (Feb. 1996).
	AS4	Leong, K.H., *et al.*, "Selective Induction of Immune Responses by Cytokines Coexpressed in Recombinant Fowlpox Virus," *J. Virol., 68*(12):8125-8130 (Dec. 1994).
	AT4	Leong, K.H., *et al.*, "Generation of Enhanced Immune Responses by Consecutive Immunization with DNA and Recombinant Fowl Pox Vectors." In *Vaccines 95,* Cold Spring Harbor Laboratory Press, p.327-331 (1995).
	AU4	Li, Shengqiang, *et al.*, "Priming With Recombinant Influenza Virus Followed By Administration of Recombinant Vaccinia Virus Induces $CD8^+$ T-Cell-Mediated Protective Immunity against Malaria," *Proc. Natl. Acad. Sci. USA 90*(11):5214-5218 (June 1993).
	AV4	Limbach, K.J. and Paoletti, E., "Non-Replicating Expression Vectors: Application in Vaccine Development and Gene Therapy," *Epidemiol. Infect. 116*:241-256 (1996).
	AW4	Mahnel, *et al.*, "Experiences with Immunization Against Orthopox Viruses of Humans and Animals Using Vaccine Strain MVA," *Berliner Und Munchener Tierarztliche Wochenschrift 107*(8):253-256 (1994) ABSTRACT ONLY
	AX4	McMichael, A., *et al.*, "Malaria and Other Tropical Diseases," *Immunol. Letters 56*(1/3):28, 425, 291 (June 22-25, 1997)(Abstract Nos. O.4.05.7, P.4.05.08, P.4.01.18 and P.4.01.22).

EXAMINER	DATE CONSIDERED
/Louise Humphrey/	06/20/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2907.1000-003	APPLICATION NO. 10/686,943	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT Adrian V.S. Hill, *et al.*		
July 2, 2004 (Use several sheets if necessary)	FILING DATE October 16, 2003	CONFIRMATION NO. 4585	GROUP 1648

OTHER DOCUMENTS ***(Including Author, Title, Date, Pertinent Pages, Etc.)***		
LWH	AY4	McShane, H., *et al.*, "Enhanced Immunogenicity of CD4$^+$ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis," *Infect. Imm. 69(2):*681-686 (2001).
	AZ4	Moorthy, M.S., *et al.*, "Safety of DNA and Modified vaccina virus Ankara Vaccines Against Liver-Stage *P. falciparum* Malaria in Non-Immune Volunteers," *Vaccine, 21(17-18):*1995-2002 (2003).
	AR5	Moorthy, M.S. and Hill, A., "Malaria Vaccines," *Br. Med. Bull., 62:*59-72 (2002).
	AS5	Moreno, A., *et al.*, "Cytotoxic CD4$^+$ T Cells From a Sporozoite-Immunized Volunteer Recognize the *Plamodium falciparum* CS Protein," *Int-Immunol, 3(10):*997-1003 (1991).
	AT5	Moss, B., *et al.*, "Host Range Restricted, Non-Replicating Vaccinia Virus Vectors as Vaccine Candidates," *Advances in Experimental Medicine and Biology 397*:7-13 (1996).
	AU5	Müller, H.M., *et al.*, "Thrombospondin Related Anonymous Protein (TRAP) of *Plasmodium falciparum* Binds Specifically to Sulfated Glycoconjugates and to HepG2 Hepatoma Cells Suggesting a Role for this Molecule in Sporozoite Invasion of Hepatocytes," *Embo J.*:2881-2889 (July 1993).
	AV5	Murata, K., *et al.*, "Characterization of *in Vivo* Primary and Secondary CD8$^+$ T Cell Responses Induced by Recombinant Influenza and Vaccinia Viruses," *Cell. Immunol. 173*(1):96-107 (Oct. 10, 1996).
	AW5	Nardin, E.H. and Nussenzweig, R.S., "T Cell Responses to Pre-Erythrocytic Stages of Malaria: Role in Protection and Vaccine Development Against Pre-Erythrocytic Stages," *Annu. Rev. Immunol. 11:*687-727 (1993).
	AX5	Plebanski, M., *et al.*, "Protection From *Plasmodium berghei* Infection By Priming and Boosting T Cells to a Single Class I-Restricted Epitope with Recombinant Carriers Suitable for Human Use," *Eur. J. Immunol., 28(12):*4345-4355 (1998).
	AY5	Richmond, J.F.L., *et al.*, "Screening of HIV-1 Env Glycoproteins for the Ability to Raise Neutralizing Antibody Using DNA Immunization and Recombinant Vaccinia Virus Boosting," *Virology 230*:265-274 (1997).
	AZ5	Rodrigues, E.G., *et al.*, "Single Immunizing Dose of Recombinant Adenovirus Efficiently Induces CD8$^+$ T Cell-Mediated Protective Immunity Against Malaria," *J. Immunol. 158*(3):1268-1274 (Feb. 1997).

EXAMINER /Louise Humphrey/	DATE CONSIDERED 06/20/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2907.1000-003	10/686,943	
	APPLICANT: Adrian V.S. Hill, *et al.*		
July 2, 2004	FILING DATE: October 16, 2003	CONFIRMATION NO.: 4585	GROUP: 1648
(Use several sheets if necessary)			

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
LWH	AR6	Rodrigues, M., *et al.*, "Influenza and Vaccinia Viruses Expressing Malaria CD8$^+$ T and B Cell Epitopes," *J. Immunol. 153*(10):4636-4648 (Nov. 15, 1994).
	AS6	Schneider, J., *et al.*, "A Prime-Boost Immunisation Regimen Using DNA Followed By Recombinant Modified Vaccinia Virus Ankara Induces Strong Cellular Immune Responses Against the *Plasmodium falciparum* TRAP Antigen In Chimpanzees," *Vaccine, 19(32):*4595-4602 (2001).
	AT6	Schneider, J., *et al.*, "Induction of CD8$^+$ T Cells Using Heterologous Prime-Boost Immunisation Strategies," *Immunological Reviews, 170:*29-38 (1999).
	AU6	Schneider, J., *et al.*, "Enhanced Immunogenicity for CD8$^+$ T Cell Induction and Complete Protective Efficacy of Malaria DNA Vaccination by Boosting with Modified Vaccinia Virus Ankara," *Nature Medicine 4*(4): 397-402 (April 1998).
	AV6	Schödel, F., *et al.*, "Immunity to Malaria Elicited by Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Protein Epitopes," *J. Exp. Med. 180*(3):1037-1046 (Sept. 1994).
	AW6	Sedegah, M., *et al.*, "Protection against Malaria by Immunization with Plasmid DNA Encoding Circumsporozoite Protein," *Proc. Natl. Acad. Sci. USA 91*(21):9866-9870 (Oct. 1994).
	AX6	Seguin, M.C., *et al.*, "Induction of Nitric Oxide Synthase Protects against Malaria in Mice Exposed to Irradiated *Plasmodium berghei* Infected Mosquitoes: Involvement of Interferon γ and CD8$^+$ T Cells," *J. Exp. Med. 180*(1):353-358 (July 1994).
	AY6	Stoute, J.A., *et al.*, "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against *Plasmodium falciparum* Malaria," *NE J. of Medicine 336*:86-91 (1997).
	AZ6	Sutter, G., *et al.*, "A Recombinant Vector Derived From the Host Range-Restricted and Highly Attenuated MVA Strain of Vaccinia Virus Stimulates Protective Immunity in Mice to Influenza Virus," *Vaccine 12*(11):1032-1040 (Aug. 1994).
	AR7	Tartaglia, J., *et al.*, "NYVAC: A Highly Attenuated Strain of Vaccinia Virus," *Virology 188*(1):217-232 (May 1992).
↓	AS7	Tascon, *et al.*, "Immunogenicity and Protective Efficacy of a Tuberculosis DNA Vaccine," *Nat. Med.* 2: 888-892 (1996).

EXAMINER	/Louise Humphrey/	DATE CONSIDERED	06/20/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2907.1000-003	10/686,943	
	APPLICANT	Adrian V.S. Hill, *et al.*	
July 2, 2004	FILING DATE	CONFIRMATION NO.	GROUP
(Use several sheets if necessary)	October 16, 2003	4585	1648

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
LWH	AT7	Tsang, K.Y., *et al.*, "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine," *J. Natl. Cancer Inst. 87*(13):982-990 (July 1995).
	AU7	Tsuji, M., *et al.*, "CD4$^+$ Cytolytic T Cell Clone Confers Protection Against Murine Malaria," *J. Exp Med., 172(5):*1353-1357 (1990).
	AV7	Wang, R., *et al.*, "Induction of CD4$^+$ T Cell-Dependent CD8$^+$ Type 1 Responses in Humans By a Malaria DNA Vaccine," *PNAS, 98:*10817-10822 (2001).
	AW7	Wizel, B., *et al.*, "Irradiated Sporozoite Vaccine Induces HLA-B8-Restricted Cytotoxic T Lymphocyte Responses against Two Overlapping Epitopes of the *Plasmodium falciparum* Sporozoite Surface Protein 2," *J. Exp. Med. 182*(5):1435-1445 (Nov. 1995).
	AX7	Zhu, X., *et al.*, "Functions and Specificity of T Cells Following Nucleic Acid Vaccination of Mice Against *Mycobacterium tuberculosis* Infection," *J. Immunol., 158:*5921-5926 (1997).
	AY7	Sequence Alignment of SEQ ID NO: 2 with Geneseq database ID NO: AAR43244 from WO 93/201103-A. Entry date: May, 1994 Inventor: Elvin, *et al.*
	AZ7	Sequence Alignment of SEQ ID NO: 4 with Geneseq database ID NO: AAR43245 from WO 93/201103-A. Entry date: May, 1994 Inventor: Elvin, *et al.*
	AR8	Sequence Alignment of SEQ ID NO: 6 with Geneseq database ID NO: AAR43243 from WO 93/201103-A. Entry date: May, 1994 Inventor: Elvin, *et al.*
	AS8	Rodriguez, D., *et al.*, "Regulated Expression of Nuclear Genes by T3 RNA Polymerase and *lac* Repressor Using Recombinant Vaccinia Virus Vectors," *J. Virol. 64*(10):4851-4857 (Oct. 1990).
	AT8	Watson, J.C., *et al.*, "General Immunization Practices," Ch. 5, in *Vaccines*, Plotkin, S.A. and Orenstein, eds., WB Saunders publ. 1999.
	AU8	Drexler, I., *et al.*, "Highly Attenuated Modified Vaccinia Virus Ankara Replicates in Baby Hamster Kidney Cells, a Potential Host for Virus Propagation, But Not in Various Human Transformed and Primary Cells," *J. Gen. Virol. 79*:347-352 (1998).

EXAMINER	DATE CONSIDERED
/Louise Humphrey/	06/20/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2907.1000-003	APPLICATION NO. 10/686,943	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT Adrian V.S. Hill, *et al.*		
July 2, 2004 (Use several sheets if necessary)	FILING DATE October 16, 2003	CONFIRMATION NO. 4585	GROUP 1648

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
LWH	AV8	Reece, WHH, *et al.*, "A DNA/MVA Prime-Boost Vaccination Regime Induces Strong Immune Responses and Partial Protection Agains *Plasmodium falciparum* in Humans," *Poster at the British Society for Immunology* (December 2001).
	AW8	"Peptide Database', Cancer Immunity, March 2001, online, retrieved from the Internet on June 23, 2003. <URL:http://cancerimmunity.org/peptidedatabase/tcellepitopes.htm>
	AX8	Zorn, E., *et al.*, 'A Natural Cytotoxic T Cell Response in a Spontaneously Regressing Human Melanoma Targets a Neoantigen Resulting Froma Somatic Point Mutation,' *Eur. J. Immunol., 29*:592-601 (1999).
	AY8	Rimoldi, D., *et al.*, 'Efficient Simulataneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma,' *J. Immunol., 165*:7253-7261 (2000).
	AZ8	Castelli, C., *et al.* 'Mass Spectrometric Identification of a Naturally Processed Melanoma Peptide Recognized by $CD8^+$ Cytotoxic T Lymphocytes', *J. Exp. Med., 181*:363-368 (1995).
	AR9	Ohminami, H., *et al.*, 'HLA Class I-Restricted Lysis of Leukemia Cells by a $CD8^+$ Cytotoxic T-Lymphocyte Clone Specific for WT1 Peptide,' *Blood, 95*:286-293 (2000).
	AS9	'Epitope Maps', HIV Molecular Immunology Database, online, retrieved from the Internet on June 23, 2003. <URL: http://hiv-web.lanl.gov/content/immunology/maps/maps.html>
	AT9	SYFPEITHI Database, 'Find Your Motif, Ligand or Epitope,.' <URL:http://syfpeithi.bmiheidelberg.com/Scripts/MHCServer.dll/findyourmotif.htm>
	AU9	Egan, M.A., *et al.*, "Induction of Human Immunodeficiency...," *Concise Communications, 171:*1623-1627, 1995
	AV9	Wang, M., *et al.*, "Active Immunotherapy of Cancer...," *The American Association of Immunologists*, p. 4685-4692, 1995
	AW9	Tartaglia, J., *et al.*, "Protection of Cats against Feline...," *Journal of Virology*, p. 2370-2375, 1993
	AX9	Brossart, P., *et al*, "Virus-Mediated Delivery of Antigenic...," *The American Association of Immunologists*, p. 3270-3276, 1997

EXAMINER	/Louise Humphrey/	DATE CONSIDERED	06/20/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2907.1000-003	10/686,943	
	APPLICANT Adrian V.S. Hill, *et al.*		
July 2, 2004	FILING DATE	CONFIRMATION NO.	GROUP
(Use several sheets if necessary)	October 16, 2003	4585	1648

OTHER DOCUMENTS ***(Including Author, Title, Date, Pertinent Pages, Etc.)***		
LWH	AY9	Chamberlain, R.S., Poster Presentation presented at the Meeting of the American Association of Cancer Research, April 20th through April 24th, 1996.
LWH	AZ9	Irvine, K., *et al.*, "Comparison of a CEA-Recombinant Vaccinia...," *Vaccine Research*, *2*(2):79-94, 1993
LWH	AR10	Franchini, G., *et al.*, "Highly Attenuated HIV Type 2...," *AIDS Research and Human Retroviruses*, *11*(8):909-920, 1995

EXAMINER	DATE CONSIDERED
/Louise Humphrey/	06/20/2006

PTO-1449/REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2907.1000-003	10/686,943
	FIRST NAMED INVENTOR: Andrew McMichael	FILING DATE: October 16, 2003
October 26, 2004	EXAMINER: Not Yet Assigned	CONFIRMATION NO.: 4585 / GROUP: 1648
(Use several sheets if necessary)		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
LWH	AH	US-2004-0131594-A1	July 8, 2004	McMichael, *et al.*
	AI	US-2004-0179349-A1	October 7, 2004	McMichael, *et al.*
	AJ	US-2004-0175365-A1	September 9, 2004	McMichael, *et al.*
	AK	US-2004-0171272-A1	September 30, 2004	McMichael, *et al.*

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
	AO					
	AP					
	AQ					

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

LWH	AS10	The Schlom Declaration cited in the opposition proceedings of European Patent Application No. EP0979284, to which the subject application claims priority.
	AT10	The Gritz Declaration cited in the opposition proceedings of European Patent Application No. EP0979284, to which the subject application claims priority.
	AU10	The Chamberlain Declaration cited in the opposition proceedings of European Patent Application No. EP0979284, to which the subject application claims priority.
	AV10	
	AW10	
	AX10	
	AY10	
	AZ10	

EXAMINER	DATE CONSIDERED
/Louise Humphrey/	06/20/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	2907.1000-003	10/686,943	
	FIRST NAMED INVENTOR	FILING DATE	
	Andrew McMichael	October 16, 2003	
May 16, 2006	EXAMINER	CONFIRMATION NO.	GROUP
(use several sheets if necessary)	Louise W. Z. Humphrey	4585	1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
LWH	AA2	4,748,019	05-31-1988	Lysons
LWH	AB2	5,462,734	10-31-1995	Letchworth, III, *et al.*

EXAMINER	/Louise Humphrey/	DATE CONSIDERED	06/19/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	2907.1000-003	10/686,943	
	FIRST NAMED INVENTOR	FILING DATE	
	Andrew McMichael	October 16, 2003	
May 16, 2006	EXAMINER	CONFIRMATION NO.	GROUP
(Use several sheets if necessary)	Louise W. Z. Humphrey	4585	1648

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
LWH	AO	WO 92/22641 A1	12-23-1992	Virogenetics Corporation		
LWH	AP	WO 98/04728 A1	02-05-1998	Therion Biologics Corporation, *et al.*		
LWH	AQ	EP 0 753 581 A1	01-15-1997	Immuno AG		

EXAMINER	/Louise Humphrey/	DATE CONSIDERED	06/19/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	2907.1000-003	10/686,943	
	FIRST NAMED INVENTOR	FILING DATE	
	Andrew McMichael	October 16, 2003	
May 16, 2006	EXAMINER	CONFIRMATION NO.	GROUP
(Use several sheets if necessary)	Louise W. Z. Humphrey	4585	1648

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
LWH	AV10	Ahlers, J.D., *et al.*, "Cytokine-in-Adjuvant Steering of the Immune Response Phenotype to HIV-1 Vaccine Constructs," *The Journal of Immunology, 158*(8):3947-3958 (1997).
	AW10	Allen, T.M. and Watkins, D.I., SIV and SHIV CTL Epitopes Identified in Macaques [online], December 1998. Retrieved from the Internet <URL:http://hiv-web.lanl.gov/content/hiv-db/COMPENDIUM/1998/III/Allen98.pdf>.
	AX10	An, L.-L., and Whitton, J.L., "A Multivalent Minigene Vaccine, Containing B-Cell, Cytotoxic T-Lymphocyte, and T_h Epitopes from Several Microbes, Induces Appropriate Responses In Vivo and Confers Protection against More than One Pathogen," *Journal of Virology, 71*(3): 2292-2302 (1997).
	AY10	Austyn, J.M. and Wood, K.J., "An Overview of Immune Responses," In *Principles of Cellular and Molecular Immunology*, (NY: Oxford University Press Inc.), pp. 42-44 (1993).
	AZ10	Bakker, A.B.H., *et al.*, "Identification of a Novel Peptide Derived from the Melanocyte-Specific GP100 Antigen as the Dominant Epitope Recognized by an HLA-A2.1-Restricted Anti-Melanoma CTL Line," *Int. J. Cancer, 62*: 97-102 (1995).
	AR11	Bergmann, C.C., *et al.*, "Flanking Residues Alter Antigenicity and Immunogenicity of Multi-Unit CTL Epitopes," *The Journal of Immunology, 157*(8): 3242-3249 (1996).
	AS11	Bukowski, J.F., *et al.*, "Natural Killer Cell Depletion Enhances Virus Synthesis and Virus-Induced Hepatitis *In Vivo*," *The Journal of Immunology, 131*(3): 1531-1538 (1983).
	AT11	Casares, N., *et al.*, "$CD4^+/CD25^+$ Regulatory Cells Inhibit Activation of Tumor-Primed $CD4^+$ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination," *The Journal of Immunology, 171*(11): 5931-5939 (2003).
	AU11	Cox, W.I., *et al.*, "Induction of Cytotoxic T Lymphocytes by Recombinant Canarypox (ALVAC) and Attenuated Vaccinia (NYVAC) Viruses Expressing the HIV-1 Envelope Glycoprotein," *Virology, 195*: 845-850 (1993).
	AV11	Egan, M.A., *et al.*, "Use of Major Histocompatibility Complex Class I/Peptide/β2M Tetramers To Quantitate $CD8^+$ Cytotoxic T Lymphocytes Specific for Dominant and Nondominant Viral Epitopes in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys," *Journal of Virology, 73*(7): 5466-5472 (1999).
↓	AW11	Eisenlohr, L.C., *et al.*, "Flanking Sequences Influence the Presentation of an Endogenously Sythesized Peptide to Cytotoxic T Lymphocytes," *The Journal of Experimental Medicine, 175*: 481-487 (1992).

EXAMINER	/Louise Humphrey/	DATE CONSIDERED	06/19/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	2907.1000-003	10/686,943	
	FIRST NAMED INVENTOR	FILING DATE	
May 16, 2006	Andrew McMichael	October 16, 2003	
(Use several sheets if necessary)	EXAMINER	CONFIRMATION NO.	GROUP
	Louise W. Z. Humphrey	4585	1648

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
LWH	AX11	Feng, C.G., *et al.*, "Induction of CD8$^+$ T-lymphocyte Responses to a Secreted Antigen of *Mycobacterium Tuberculosis* by an Attenuated Vaccinia Virus," *Immunology and Cell Biology, 79*: 569-575 (2001).
	AY11	Gherardi, M.M., *et al.*, "Prime Boost Immunization Schedules Based on Influenza Virus and Vaccinia Virus Vectors Potentiate Cellular Immune Responses Against Human Immunodeficiency Virus Env Protein Systemically and in the Genitorectal Draining Lymph Nodes," *The Journal of Virology, 77*(12): 7048-7057 (2003).
	AZ11	Gönczöl, E., *et al.*, "Preclinical Evaluation of an ALVAC (canarypox)-human Cytomegalovirus Glycoprotein B Vaccine Candidate," *Vaccine, 13*(12): 1080-1085 (1995).
	AR12	HIV CTL Epitopes Table 2 p24. [online], December 1996. Retrieved from the Internet <URL:http://hiv-web.lanl.gov/content/immunology/pdf/1996/CTL/TABLES/p24.pdf>.
	AS12	HIV CTL Epitopes Table 3: p24 [online], December 1999. Retrieved from the Internet <URL:http://hiv-web.lanl.gov/content/immunology/pdf/1999/1/tables/p24.pdf>.
	AT12	HIV CTL Epitopes Table 4: Pol [online], December 1997. Retrieved from the Internet <URL:http://hiv-web.lanl.gov/content/hiv-db/immunology/PDF/1997/CTL/tables/pol.pdf>.
	AU12	HIV CTL Epitopes Table 6 gp120. [online], December 1996. Retrieved from the Internet <URL:http://hiv-web-lanl.gov/content/immunology/pdf/1996/CTL/TABLES/gp120.pdf>.
	AV12	HIV CTL Epitopes Table 7 gp41. [online], December 1996. Retrieved from the Internet <URL:http://hiv-web.lanl.gov/content/immunology/pdf/1996/CTL/TABLES/gp41.pdf>.
	AW12	HIV CTL Epitopes Table 8 Nef. [online], December 1996. Retrieved from the Internet <URL:http://hiv-web.lanl.gov/content/immunology/pdf/1996/CTL/TABLES/nef.pdf>.
	AX12	Hu, S.-L., *et al.*, "Protection of Macaques Against SIV Infection by Subunit Vaccines of SIV Envelope Glycoprotein gp160," *Science, 255*: 456-459 (1992).
	AY12	Hunter, C.A., "How are NK Cell Responses Regulated During Infection?," *Experimental Parasitology, 84*: 444-448 (1996).
	AZ12	Janeway, C.A., *et al.*, "General Properties of Armed Effector T Cells," In *Immuno Biology*, (NY: Garland Publishing a member of the Taylor & Francis Group) p. 319 (2001).

EXAMINER	/Louise Humphrey/	DATE CONSIDERED	06/19/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	2907.1000-003	10/686,943	
	FIRST NAMED INVENTOR	FILING DATE	
	Andrew McMichael	October 16, 2003	
May 16, 2006	EXAMINER	CONFIRMATION NO.	GROUP
(Use several sheets if necessary)	Louise W. Z. Humphrey	4585	1648

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
LWH	AR13	Konishi, E., *et al.*, "Induction of Japanese Encephalitis Virus-specific Cytotoxic T Lymphocytes in Humans by Poxvirus-based JE Vaccine Candidates," *Vaccine, 16*(8): 842-849 (1998).
	AS13	Konishi, E., *et al.*, "Poxvirus-Based Japanese Encephalitis Vaccine Candidates Induce JE Virus-Specific $CD8^+$ Cytotoxic T Lymphocytes in Mice," *Virology, 227*: 353-360 (1997).
	AT13	Kuby, J.,"Cell-Mediated and Humoral Effector Responses," In *Immunology*, (NY: W. H. Freeman and Company) pp. 379-412 (1997).
	AU13	Linnemeyer, P.A., "The Immune System - An Overview," [online] November 1993 [retrieved on 2006-04-12]. Retrieved from the Internet <URL:http://www.thebody.com/step/immune.html>.
	AV13	Malcherek, G., *et al.*, "Supermotifs Enable Natural Invariant Chain-derived Peptides to Interact with Many Major Histocompatibility Complex-Class II Molecules," *J. Exp. Med., 181*: 527-536 (1995).
	AW13	Martin, R.M. and Lew, A.M., "Is IgG2a a Good Th1 Marker in Mice?" *Immunology Today, 19*:49 (1998).
	AX13	Müller, H.M., *et al.*, "Thrombospondin Related Anonymous Protein (TRAP) of *Plasmodium Falciparum* in Parasite-Host Cell Interactions," *Parassitologia 35(Suppl.)*: 69-72 (1993).
	AY13	Narvaiza, I., *et al.*, Intratumoral Coinjection of Two Adenoviruses, One Encoding the Chemokine IFN-γ-Inducible Protein-10 and Another Encoding IL-12, Results in Marked Antitumoral Synergy," *The Journal of Immunology, 164*(6): 3112-3122 (2000).
	AZ13	Ojcius, D. M., *et al.*, "Is Antigen Processing Guided by Major Histocompatibility Complex Molecules?," *FASEB J., 8*: 974-978 (1994).
	AR14	Okuda, K., *et al.*, "Induction of Potent Humoral and Cell-Mediated Immune Responses Following Direct Injection of DNA Encoding the HIV Type 1 *env* and *rev* Gene Products," *Aids Research and Human Retroviruses, 11*(8): 933-943 (1995).
	AS14	Ramirez, J.C., *et al.*, "Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a Vaccine," *Journal of Virology, 74*(2): 923-933 (2000).
	AT14	Reusser, P., *et al.*, "Cytomegalovirus-Specific T-Cell Immunity in Recipients of Autologous Peripheral Blood Stem Cell or Bone Marrow Transplants," *Blood, 89*(10): 3873-3879 (1997).

EXAMINER	/Louise Humphrey/	DATE CONSIDERED	06/19/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	2907.1000-003	10/686,943	
	FIRST NAMED INVENTOR	FILING DATE	
	Andrew McMichael	October 16, 2003	
May 16, 2006	EXAMINER	CONFIRMATION NO.	GROUP
(Use several sheets if necessary)	Louise W. Z. Humphrey	4585	1648

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
LWH	AU14	Romero, P., *et al.*, "Cloned Cytotoxic T Cells Recognize an Epitope in the Circumsporozoite Protein and Protect Against Malaria," *Nature, 341*: 323-326 (1989).
	AV14	Takada, K., *et al.*, "Definition of an Epitope on Japanese Encephalitis Virus (JEV) Envelope Protein Recognized by JEV-specific Murine CD8+ Cytotoxic T Lymphocytes," *Arch Virol., 145*: 523-534 (2000).
	AW14	Vasmatzis, G., *et al.*, "Computational Determination of Side Chain Specificity for Pockets in Class I MHC Molecules," *Molecular Immunology, 33*(16): 1231-1239 (1996).
	AX14	Whitton, J.L., *et al.*, "A "String-of-Beads" Vaccine, Comprising Linked Minigenes, Confers Protection from Lethal-Dose Virus Challenge," *Journal of Virology, 67*(1): 348-352 (1993).
	AY14	Yang, Y., *et al.*, "Upregulation of Class I Major Histocompatibility Complex Antigens by Interferon γ is Necessary for T-cell-mediated Elimination of Recombinant Adenovirus-infected Hepatocytes *In Vivo*," *Proc. Natl. Acad. Sci. USA, 92*: 7257-7261 (1995).
	AZ14	Yellen-Shaw, A.J., *et al.*, "Point Mutation Flanking a CTL Epitope Ablates In Vitro and In Vivo Recognition of a Full-Length Viral Protein," *The Journal of Immunology, 158*(7): 3227-3234 (1997).
	AR15	Zhu, M., *et al.*, "Specific Cytoltic T-Cell Responses to Human CEA from Patients Immunized with Recombinant Avipox-CEA Vaccine," *Clinical Cancer Research, 6*: 24-33 (2000).
	AS15	Thomson, S.A., *et al.*, "Recombinant Polyepitope Vaccines for the Delivery of Multiple CD8 Cytotoxic T Cell Epitopes," *J. Immunol.*, *157*(2):822-826 (1996).

EXAMINER	/Louise Humphrey/	DATE CONSIDERED	06/19/2006